journal
MENU ▼
Read by QxMD icon Read
search

Applied Health Economics and Health Policy

journal
https://www.readbyqxmd.com/read/28900901/erratum-to-estimated-healthcare-costs-of-melanoma-in-australia-over-3-years-post-diagnosis
#1
Thomas M Elliott, David C Whiteman, Catherine M Olsen, Louisa G Gordon
The last word in the first paragraph which previously read AU$25 million should read 25 million as this relates to population size.
September 12, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28871514/a-scoping-review-of-economic-evaluations-alongside-randomised-controlled-trials-of-home-monitoring-in-chronic-disease-management
#2
REVIEW
Kristian Kidholm, Mie Borch Dahl Kristensen
Many countries have considered telemedicine and home monitoring of patients as a solution to the demographic challenges that health-care systems face. However, reviews of economic evaluations of telemedicine have identified methodological problems in many studies as they do not comply with guidelines. The aim of this study was to examine economic evaluations alongside randomised controlled trials of home monitoring in chronic disease management and hereby to explore the resources included in the programme costs, the types of health-care utilisation that change as a result of home monitoring and discuss the value of economic evaluation alongside randomised controlled trials of home monitoring on the basis of the studies identified...
September 4, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28871512/decision-making-and-priority-setting-the-evolving-path-towards-universal-health-coverage
#3
Francesco Paolucci, Ken Redekop, Ayman Fouda, Gianluca Fiorentini
Health technology assessment (HTA) is widely viewed as an essential component in good universal health coverage (UHC) decision-making in any country. Various HTA tools and metrics have been developed and refined over the years, including systematic literature reviews (Cochrane), economic modelling, and cost-effectiveness ratios and acceptability curves. However, while the cost-effectiveness ratio is faithfully reported in most full economic evaluations, it is viewed by many as an insufficient basis for reimbursement decisions...
September 4, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28866822/dutch-economic-value-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#4
Michel L Peters, Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M Leliveld-Kors, Joan van den Bosch, Pieter H van den Berg, Agni Baka, Jennifer G Gaultney
BACKGROUND: The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel from the Dutch societal perspective was investigated. METHODS: A cost-effectiveness analysis was conducted using efficacy, symptomatic skeletal-related event and safety data obtained from indirect treatment comparisons...
September 2, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28856585/a-systematic-review-of-cost-of-illness-studies-of-multimorbidity
#5
REVIEW
Lili Wang, Lei Si, Fiona Cocker, Andrew J Palmer, Kristy Sanderson
OBJECTIVES: The economic burden of multimorbidity is considerable. This review analyzed the methods of cost-of-illness (COI) studies and summarized the economic outcomes of multimorbidity. METHODS: A systematic review (2000-2016) was performed, which was registered with Prospero, reported according to PRISMA, and used a quality checklist adapted for COI studies. The inclusion criteria were peer-reviewed COI studies on multimorbidity, whereas the exclusion criterion was studies focusing on an index disease...
August 30, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28828741/health-expenditure-and-all-cause-mortality-in-the-galaxy-of-italian-regional-healthcare-systems-a-15-year-panel-data-analysis
#6
Davide Golinelli, Fabrizio Toscano, Andrea Bucci, Jacopo Lenzi, Maria Pia Fantini, Nicola Nante, Gabriele Messina
BACKGROUND: The sustainability of healthcare systems is a topic of major interest. During periods of economic instability, policy makers typically reallocate resources and execute linear cuts in different areas of public spending, including healthcare. OBJECTIVES: The aim of this paper was to examine whether and how per capita public healthcare expenditure (PHE) in the Italian regions was related to the all-cause mortality rate (MR) between 1999 and 2013 and to determine which expenditure item most affected mortality in the short and very short term...
August 21, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28828573/a-cost-benefit-analysis-of-two-alternative-models-of-maternity-care-in-ireland
#7
Christopher G Fawsitt, Jane Bourke, Aileen Murphy, Brendan McElroy, Jennifer E Lutomski, Rosemary Murphy, Richard A Greene
BACKGROUND: The Irish government has committed to expand midwifery-led care alongside consultant-led care nationally, although very little is known about the potential net benefits of this reconfiguration. OBJECTIVES: To formally compare the costs and benefits of the major models of care in Ireland, with a view to informing priority setting using the contingent valuation technique and cost-benefit analysis. METHODS: A marginal payment scale willingness-to-pay question was adopted from an ex ante perspective...
August 21, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28822113/economic-evaluation-of-interventions-for-children-with-neurodevelopmental-disorders-opportunities-and-challenges
#8
Ramesh Lamsal, Jennifer D Zwicker
Economic evaluation is a tool used to inform decision makers on the efficiency of comparative healthcare interventions and inform resource allocation decisions. There is a growing need for the use of economic evaluations to assess the value of interventions for children with neurodevelopmental disorders (NDDs), a population that has increasing demands for healthcare services. Unfortunately, few evaluations have been conducted to date, perhaps stemming from challenges in applying existing economic evaluation methodologies in this heterogeneous population...
August 18, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28822106/multiple-criteria-decision-analysis-in-health-technology-assessment-for-drugs-just-another-illusion
#9
EDITORIAL
Livio Garattini, Anna Padula
No abstract text is available yet for this article.
August 18, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28756584/estimated-healthcare-costs-of-melanoma-in-australia-over-3%C3%A2-years-post-diagnosis
#10
Thomas M Elliott, David C Whiteman, Catherine M Olsen, Louisa G Gordon
BACKGROUND: Skin cancer exerts a large and growing burden on health systems. With new pharmacotherapies for metastatic melanoma now available, a contemporary understanding of the cost burden of melanoma control is warranted. OBJECTIVE: To comprehensively assess the healthcare costs of malignant melanoma diagnosis and treatment in Australia, over 3 years after diagnosis. METHODS: We developed a decision-analytic model and micro-costing method to estimate the mean cost per patient for melanoma, incorporating all diagnostic and treatment modalities used in Australia (2017 AU$)...
July 29, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28702875/private-health-insurance-incentives-in-australia-in-search-of-cost-effective-adjustments
#11
P Marcin Sowa, Sam Kault, Joshua Byrnes, Shu-Kay Ng, Tracy Comans, Paul A Scuffham
BACKGROUND: The appropriate structure, scope and cost of government incentives in the private health insurance (PHI) market is a matter of ongoing debate. OBJECTIVE: In order to inform policy decisions we designed a two-stage study to (1) model the uptake of PHI covering hospital treatment in Australia, and (2) identify the costs of various policy scenarios to the government. METHODS: Using a microsimulation with a cost-benefit component, we modelled the insurance decisions made by individuals who collectively represented the Australian insurance population in the financial year 2014-15...
July 12, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28702874/towards-a-transparent-credible-evidence-based-decision-making-process-of-new-drug-listing-on-the-hong-kong-hospital-authority-drug-formulary-challenges-and-suggestions
#12
Carlos King Ho Wong, Olivia Wu, Bernard M Y Cheung
The aim of this article is to describe the process, evaluation criteria, and possible outcomes of decision-making for new drugs listed in the Hong Kong Hospital Authority Drug Formulary in comparison to the health technology assessment (HTA) policy overseas. Details of decision-making processes including the new drug listing submission, Drug Advisory Committee (DAC) meeting, and procedures prior to and following the meeting, were extracted from the official Hong Kong Hospital Authority drug formulary management website and manual...
July 12, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28695351/robustness-and-effectiveness-of-the-triage-system-in-the-pediatric-context
#13
Marcello Montefiori, Enrico di Bella, Lucia Leporatti, Paolo Petralia
BACKGROUND: The increasing use of emergency departments (EDs) potentially compromises their effectiveness and quality. The evaluation of the performance of the triage code system in a pediatric context is important because waiting time affects the quality of care for acutely ill patients. OBJECTIVE: In this study, we aimed to assess the effectiveness and robustness of the triage code system in a pediatric context and identify the determinants of waiting times for urgent and non-urgent patients...
July 10, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28669043/the-xpress-multi-sinus-dilation-system-for-the-treatment-of-chronic-sinusitis-a-nice-medical-technology-guidance
#14
REVIEW
Michelle Jenks, Iain Willits, Emily Eaton Turner, Neil Hewitt, Mick Arber, Helen Cole, Joyce Craig, Andrew Sims
The XprESS multi-sinus dilation system (XprESS) is a minimally invasive alternative to functional endoscopic sinus surgery (FESS) used in the treatment of people with chronic or recurrent acute sinusitis refractory to medical treatment. The manufacturer of XprESS, Entellus Medical, claims the technology is as effective as FESS in improving quality of life and is associated with quicker recovery times and reduced costs. The Medical Technologies Advisory Committee (MTAC) at the National Institute for Health and Care Excellence (NICE) selected XprESS for evaluation...
July 1, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28660496/role-of-cost-on-failure-to-access-prescribed-pharmaceuticals-the-case-of-statins
#15
Ian McRae, Kees van Gool, Jane Hall, Laurann Yen
BACKGROUND: In Australia, as in many other Western countries, patient surveys suggest the costs of medicines lead to deferring or avoiding filling of prescriptions. The Australian Pharmaceutical Benefits Scheme provides approved prescription medicines at subsidised prices with relatively low patient co-payments. The Pharmaceutical Benefits Scheme defines patient co-payment levels per script depending on whether patients are "concessional" (holding prescribed pension or other government concession cards) or "general", and whether they have reached a safety net defined by total out-of-pocket costs for Pharmaceutical Benefits Scheme-approved medicines...
June 28, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28290107/estimating-willingness-to-pay-for-online-health-services-with-discrete-choice-experiments
#16
Jieun Chang, Scott J Savage, Donald M Waldman
BACKGROUND: Research has outlined the benefits and costs of online health services, but these studies have typically focused on a specific geographic region or disease. Very few studies have estimated consumer demand for online health services. OBJECTIVE: This study estimated household's willingness to pay (WTP) for the ability to receive remote diagnosis, treatment, monitoring and consultations online (telehealth). METHODS: WTP was estimated with a random utility model and household data from a US survey employing repeated discrete-choice experiments...
August 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28290104/erratum-to-spectra-optia-%C3%A2-for-automated-red-blood-cell-exchange-in-patients-with-sickle-cell-disease-a-nice-medical-technology-guidance
#17
Iain Willits, Helen Cole, Roseanne Jones, Kimberley Carter, Mick Arber, Michelle Jenks, Joyce Craig, Andrew Sims
No abstract text is available yet for this article.
August 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28110486/spectra-optia-%C3%A2-for-automated-red-blood-cell-exchange-in-patients-with-sickle-cell-disease-a-nice-medical-technology-guidance
#18
REVIEW
Iain Willits, Helen Cole, Roseanne Jones, Kimberley Carter, Mick Arber, Michelle Jenks, Joyce Craig, Andrew Sims
The Spectra Optia(®) automated apheresis system, indicated for red blood cell exchange in people with sickle cell disease, underwent evaluation by the National Institute for Health and Care Excellence, which uses its Medical Technologies Advisory Committee to make recommendations. The company (Terumo Medical Corporation) produced a submission making a case for adoption of its technology, which was critiqued by the Newcastle and York external assessment centre. Thirty retrospective observational studies were identified in their clinical submission...
August 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28035629/cost-effectiveness-of-different-population-screening-strategies-for-hereditary-haemochromatosis-in-australia
#19
Barbara de Graaff, Amanda Neil, Lei Si, Kwang Chien Yee, Kristy Sanderson, Lyle Gurrin, Andrew J Palmer
INTRODUCTION: Amongst populations of northern European ancestry, HFE-associated haemochromatosis is a common genetic disorder characterised by iron overload. In the absence of treatment, excess iron is stored in parenchymal tissues, causing morbidity and mortality. Population screening programmes may increase early diagnosis and reduce associated disease. No contemporary health economic evaluation has been published for Australia. The objective of this study was to identify cost-effective screening strategies for haemochromatosis in the Australian setting...
August 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28578497/authors-reply-to-luft-measuring-the-volume-outcome-relation-for-complex-hospital-surgery
#20
LETTER
Vivian Ho, Woohyeon Kim, Stephen Wolff
No abstract text is available yet for this article.
June 3, 2017: Applied Health Economics and Health Policy
journal
journal
40237
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"